Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists

por Büttelmann, M., Hofheinz, R.D., Kröcher, A., Ubbelohde, U., Stintzing, S., Reinacher-Schick, A., Bornhäuser, M., Folprecht, G.
Publicado 2023

An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants

por Stasik, S., Schuster, C., Ortlepp, C., Platzbecker, U., Bornhäuser, M., Schetelig, J., Ehninger, G., Folprecht, G., Thiede, C.
Publicado 2018

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

por Lordick, F, Luber, B, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Wöll, E, Decker, T, Endlicher, E, Röthling, N, Schuster, T, Keller, G, Fend, F, Peschel, C
Publicado 2010

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials

por Giatromanolaki, A, Koukourakis, M I, Sivridis, E, Gatter, K C, Trarbach, T, Folprecht, G, Shi, M M, Lebwohl, D, Jalava, T, Laurent, D, Meinhardt, G, Harris, A L
Publicado 2012

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

por Schultheis, B., Folprecht, G., Kuhlmann, J., Ehrenberg, R., Hacker, U. T., Köhne, C. H., Kornacker, M., Boix, O., Lettieri, J., Krauss, J., Fischer, R., Hamann, S., Strumberg, D., Mross, K. B.
Publicado 2013

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic...

por Klinghammer, K., Fayette, J., Kawecki, A., Dietz, A., Schafhausen, P., Folprecht, G., Rottey, S., Debourdeau, P., Lavernia, J., Jacobs, A., Ahrens-Fath, I., Dietrich, B., Baumeister, H., Zurlo, A., Ochsenreither, S., Keilholz, U.
Publicado 2021

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

por Huebner, G, Link, H, Kohne, C H, Stahl, M, Kretzschmar, A, Steinbach, S, Folprecht, G, Bernhard, H, Al-Batran, S E, Schoffski, P, Burkart, C, Kullmann, F, Otremba, B, Menges, M, Hoffmann, M, Kaiser, U, Aldaoud, A, Jahn, A
Publicado 2009

Report from the OECI Oncology Days 2014

por van Harten, WH, Stanta, G, Bussolati, G, Riegman, P, Hoefler, G, Becker, KF, Folprecht, G, Truini, M, Haybaeck, J, Buiga, R, Dono, M, Bagg, A, López Guerrero, JA, Zupo, S, Lemare, F, de Lorenzo, F, Goedbloed, N, Razavi, D, Lövey, J, Cadariu, PA, Rollandi, GA, Paparo, F, Pierotti, M, Ciuleanu, T, De Paoli, P, Weiner, G, Saghatchian, M, Lombardo, Claudio
Publicado 2014